DRUG
Bright Minds Biosciences Inc

7,684
Mkt Cap
$784.12M
Volume
74,114.00
52W High
$123.75
52W Low
$23.18
PE Ratio
-65.24
DRUG Fundamentals
Price
$77.90
Prev Close
$80.57
Open
$80.83
50D MA
$82.64
Beta
0.99
Avg. Volume
250,643.10
EPS (Annual)
-$1.27
P/B
10.43
$357.67
Loading...
Loading...
News
all
press releases
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold
Wall Street Zen upgraded Bright Minds Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 6.2% - Time to Sell?
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 6.2% - Here's Why...
MarketBeat·15h ago
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Issues Earnings Results, Beats Estimates By $0.28 EPS
Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts...
MarketBeat·18h ago
News Placeholder
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six analysts that are presently covering the firm, MarketBeat...
MarketBeat·8d ago
News Placeholder
Bright Minds Biosciences (DRUG) Projected to Post Quarterly Earnings on Thursday
Bright Minds Biosciences (NASDAQ:DRUG) will be releasing its Q1 2026 earnings before the market opens on Thursday, February 12. (View Earnings Report at...
MarketBeat·9d ago
News Placeholder
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 67.5%
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest...
MarketBeat·14d ago
News Placeholder
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG
Bright Minds Biosciences (NASDAQ:DRUG) reported top-line results from an open-label Phase 2 breakthrough study evaluating BMB-101 in adults with highly refractory absence seizures and developmental...
MarketBeat·1mo ago
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Price Target Raised to $147.00
BTIG Research upped their price objective on Bright Minds Biosciences from $72.00 to $147.00 and gave the stock a "buy" rating in a research note on Tuesday...
MarketBeat·1mo ago
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Hits New 12-Month High - What's Next?
Bright Minds Biosciences (NASDAQ:DRUG) Sets New 52-Week High - Time to Buy...
MarketBeat·1mo ago
News Placeholder
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday
read more...
Benzinga·1mo ago
<
1
2
...
>

Latest DRUG News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.